irsogladine has been researched along with rolipram in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitazawa, S; Kyoi, T; Tajima, K; Ukai, Y; Zhang, X | 1 |
| Kyoi, T; Noda, K; Oka, M; Ukai, Y | 1 |
2 other study(ies) available for irsogladine and rolipram
| Article | Year |
|---|---|
Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Anti-Ulcer Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Gastric Mucosa; Male; Omeprazole; Peroxidase; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rolipram; Stomach Ulcer; Triazines; Tumor Necrosis Factor-alpha | 2004 |
Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Anti-Ulcer Agents; Bucladesine; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Gastric Mucosa; Humans; Isoenzymes; Isoquinolines; Neutrophils; Rolipram; Sulfonamides; Superoxides; Triazines | 2004 |